Shares of BeiGene, a biopharmaceutical company, experienced a pre-market soar of 5.62% on October 4th, 2024. This upward movement in the stock price can be attributed to the company's announcement of granting share options and restricted share units (RSUs) to its employees and directors.
According to filings with the Hong Kong stock exchange, BeiGene granted 22,713 American depositary shares (ADSs), equivalent to 295,269 underlying shares, as share options to 12 employees. These options will vest over a period of 10 years. Additionally, the company granted 90,542 restricted share units in ADSs, equivalent to 1,177,046 underlying shares, to 223 recipients.
The granting of share options and RSUs is a common practice for companies to incentivize and retain their employees and directors. This announcement from BeiGene is seen as a positive signal by investors, reflecting the company's efforts to motivate its workforce and align their interests with those of the shareholders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。